Association between concentration of melatonin, and lipoproteins, LPO, hsCRP, NTproBNP in chronic heart failure patients
References
- 1. Aqil A., Reiter R.J., Jimenez-Aranda A., Iban-Arias R., Navarro- Alarcon M., Adem A., Fernandez-Vazquez G. Melatonin ameliorates low-grade inflammation and oxidative stress in young Zucker diabetic fatty rats. J. Pineal Res., 54, 381, 2013.
- 2. Berrougui H., Claudia N. Momo CN., Khalil A.: Health benefits of high-density lipoproteins in preventing cardiovascular diseases. J. Clin. Lipidol. 6, 524, 2012.
- 3. Birjmohun R.S., Dallinga-Thie G.M., Kuivenhoven J.A., et al.: Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation, 116, 2029, 2007.
- 4. Dominguez-Rodriguez A.: Melatonin in cardiovascular disease. Expert. Opin. Investig., 21, 1593, 2012.
- 5. Dominguez-Rodriguez A., Abreu-Gonzalez P., Avanzas P.: The role of melatonin in acute myocardial infarction. Front. Biosci., 17, 2433, 2012.
- 6. Dzida G., Prystupa A., Lachowska-Kotowska P., Kardas T., Kamieński P., Kimak E., Hałabiś M., Kiciński P.: Alteration in diurnal and nocturnal melatonin serum level in patients with chronic heart failure. AAEM., 20, 745, 2013.
- 7. Espino J., Pariente JA., Rodriguez A.B.: Oxidative stress and immunosenescence: therapeutic effects of melatonin. Oxidative Med. Cell. Longev., 2012, 6702941, 9p, 2012.
- 8. Friedewald W.T., Levy R.I., Friedrickson D.S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin. Chem., 18, 499, 1972.
- 9. Gauthamadasa K., Vaitinadin N.S., Dressman J.L., Macha S., Homan R., Greis K.D., Silva G.D.: Apolipoprotein AII-mediated conformation changes of apolipoprotein AI in discoidal high density lipoproteins. J. Biol. Chem., 287, 7615, 2012.
- 10. Kimak E., Bylina J., Solski J., Hałabiś M., Baranowicz-Gąszczyk I., Książek A. Association between lipids, lipoproteins composition of HDL particles and triglyceride-rich lipoproteins, and LCAT and CETP activity in post-renal transplant patients. CBB., 67, 695, 2013.
- 11. Kimak E., Hałabiś M., Baranowicz-Gąszczyk I., Solski J., Książek A.: Association between moderately oxidized low-density lipoprotein and high-density lipoprotein particle subclass distribution in hemodialyzed and post-renal transplant patients. JZUS-B., 12, 365, 2011.
- 12. Korkmaz A., Reiter R.J., Topal T., Manchester L.C., Oter S., Tan D.X.: Melatonin, an established antioxidant worthy of use in clinical trials. Mol. Med., 15, 43, 2009.
- 13. Maiga S.F., Kalopissis A-D., Chabert M.: Apolipoprotein AII is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes. Biochimie., 96, 56, 2014.
- 14. Marchetti C., Sidahmed-Adrar N., Collin F., Jore D., Garde`s-Albert M., Bonnefont-Rousselot D.: Melatonin protects PLPC liposomes and LDL towards radical-induced oxidation. J. Pineal. Res., 51, 286, 2011.
- 15. Morceli G., Honorio-Franca A.C., Fagundes D.L., Calderon I.M., Franca E.L.: Antioxidant effect of melatonin on the functional activity of colostral phagocytes in diabetic women. PloSOne 8, e56915. Epub 2013.
- 16. Mozaffari S., Hasani-Ranjbar S., Abdollahi M.: The mechanisms of positive effects of melatonin in dyslipidemia: a systemic review of animal and human studies. Int. J. Pharmacol., 8, 496, 2012.
- 17. Ng T.W.K., Chan D.C., Hugh P., Barrett R., Watts G.F.: Effect of weight loss on HDL-apoAII kinetics in the metabolic syndrome. Clin. Sci., 118, 79, 2010.
- 18. Papaharlambus C.A , Griendling K.K.: Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc. Med., 17, 48, 2007.
- 19. Podrez E. A.: Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin. Exp. Pharmacol. Physiol., 37, 719, 2010.
- 20. Reiter R. J., Tan D-X., Paredes S.D.: Beneficial effects of melatonin in cardiovascular disease. Ann. Med., 42, 276, 2010.
- 21. Shuhei N., Söderlund S., Jauhiainen M., Taskinen M-R.: Effect of HDL composition and particle size on the resistance of HDL to the oxidation. Lipid Health Dis., 9, 104, 2010.
- 22. Tamura H., Nakamura Y., Narimatsu A., Yamagata Y., Takasaki A., Reiter R.J.: Melatonin treatment in peri- and postmenopausal women elevates serum high density lipoprotein cholesterol levels without influencing total cholesterol levels. J. Pineal. Res., 45, 101, 2008.
- 23. Wakatsuki A., Okatani Y., Ikenoue N., Shinohara K., Watanabe K., Fukaya T.: Melatonin protects against oxidized low-density lipoprotein-induced inhibition of nitric oxide production in human umbilical artery. J. Pineal Res., 3,: 281, 2001.
- 24. Wu W.S., Chou M.T., Chao C.M., Chang C.K., Lin M.T., Chang C.P.: Melatonin reduces acute lung inflammation, edema, and hemorrhage in heatstroke rats. Acta Pharmacol. Sin., 33, 775, 2012.
Language: English
Page range: 159 - 164
Submitted on: Oct 23, 2014
Accepted on: Nov 4, 2014
Published online: Mar 3, 2015
Published in print: Sep 1, 2014
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2015 Elzbieta Kimak, Grzegorz Dzida, Dariusz Duma, Andrzej Prystupa, Magdalena Halabis, Aleksandra Kimak, Bartosz Zieba, Iwona Kaznowska-Bystryk, Agnieszka Kowalska, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.